Table of contents

Clinical and epidemiological research

• Extended report: Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study (28 October, 2014) Free

  Alexis Ogdie, YiDing Yu, Kevin Haynes, Thorvardur Jon Love, Samantha Maliha, Yihui Jiang, Andrea B Troxel, Sean Hennessy, Steven E Kimmel, David J Margolis, Hyon Choi, Nehal N Mehta, Joel M Gelfand
• Extended report: Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate (27 November, 2014)

  Edward C Keystone, Peter C Taylor, Edit Drescher, Douglas E Schlichting, Scott D Beattie, Pierre-Yves Berclaz, Chin H Lee, Rosanne K Fidelus-Gort, Monica E Luchi, Terence P Rooney, William L Macias, Mark C Genovese
• Extended report: Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study (27 November, 2013)

  K V C Wevers-de Boer, L Heimans, K Visser, J Kälvesten, R J Goekoop, M van Oosterhout, J B Harbers, C Bijkerk, M Steup-Beekman, M P D M de Buck, P B J de Sonnaville, T W J Huizinga, C F Allaart
• Extended report: Worsening of pain and function over 5 years in individuals with ‘early’ OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study (15 November, 2013)

  Janet Wesseling, Sita M A Bierma-Zeinstra, Margreet Kloppenburg, Rik Meijer, Johannes W J Bijlsma
• Extended report: Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab (27 November, 2013)

  M Neovius, E V Arkema, H Olsson, J K Eriksson, L E Kristensen, J F Simard, J Askling
• Extended report: Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects (21 November, 2013)

  C L M Krieckaert, S C Nair, M T Nurmohamed, C J J van Dongen, W F Lems, F P J G Lafeber, J W J Bijlsma, H Koffijberg, G Wolbink, P M J Welsing
• Extended report: Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan (21 November, 2013)

  Chang-Fu Kuo, Matthew J Grainge, Lai-Chu See, Kuang-Hui Yu, Shue-Fen Luo, Ana M Valdes, Weiya Zhang, Michael Doherty
• Extended report: Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins (25 November, 2013)

  Aase Haj Hensvold, Patrik K E Magnusson, Vijay Joshua, Monika Hansson, Lena Israelsson, Ricardo Ferreira, Per-Johan Jakobsson, Rikard Holmdahl, Lennart Hammarström, Vivianne Malmström, Johan Askling, Lars Klareskog, Anca Irinel Catrina
• Extended report: Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010 (27 November, 2013)

  Anna-Birgitte Aga, Elisabeth Lie, Till Uhlig, Inge Christoffer Olsen, Ada Wierød, Synøve Kalstad, Erik Rødevand, Knut Mikkelsen, Tore K Kvien, Espen A Haavardsholm
• Extended report: Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study (28 November, 2013)

  Yoshiya Tanaka, Shintaro Hirata, Satoshi Kubo, Shunsuke Fukuyo, Kentaro Hanami, Norifumi Sawamukai, Kazuhisa Nakano, Shingo Nakayamada, Kunihiro Yamaoka, Fusae Sawamura, Kazuyoshi Saito
• Extended report: Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up (10 December, 2013)

  Eva L Kneepkens, James Cheng-Chung Wei, Michael T Nurmohamed, Kai-Jieh Yeo, C Y Chen, Irene E van der Horst-Bruinsma, Desiree van der Kleij, Theo Rispens, Gertjan Wolbink, Charlotte L M Krieckaert
• Extended report: Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients (28 November, 2013)

  Maja Bulatović Ćalasan, Ethan den Boer, Maurits C F J de Rotte, Sebastiaan J Vastert, Sylvia Kamphuis, Robert de Jonge, Nico M Wulffraat
• Extended report: Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis (2 December, 2013)

  Maurits C F J de Rotte, Ethan den Boer, Pascal H P de Jong, Saskia M F Pluijm, Maja Bulatović Ćalasan, Angelique E Weel, A Margriet Huisman, Andreas H Gerards, Barbara van Schaeybroeck, Nico M Wulffraat, Jan Lindemans, Johanna M W Hazes, Robert de Jonge
• Extended report: Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab (29 November, 2013)

  Joachim Listing, Jörn Kekow, Bernhard Manger, Gerd-Rüdiger Burmester, Dagmar Pattloch, Angela Zink, Anja Strangfeld
• Extended report: Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss (2 December, 2013)

  Jean-Pierre Pelletier, Camille Roubille, Jean-Pierre Raynauld, François Abram, Marc Dorais, Philippe Delorme, Johanne Martel-Pelletier
• Extended report: The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor (2 December, 2013)

  Leslie R Harrold, George W Reed, Joel M Kremer, Jeffrey R Curtis, Daniel H Solomon, Marc C Hochberg, Jeffrey D Greenberg
• Extended report: Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years (2 December, 2013)

  Sovira Tan, Jianhua Yao, John A Flynn, Lawrence Yao, Michael M Ward